Javascript must be enabled to continue!
Prognostic Impact of a Lymphocyte Activation-Associated Gene Signature in GBM based on Transcriptome Analysis
View through CrossRef
Abstract
Background Glioblastoma multiforme (GBM) is the most aggressive primary central nervous system malignant tumor that has poor prognosis. Lymphocyte activation played important roles in cancer and therapy. Objective To identify an efficient lymphocyte activation-associated gene signature that could predict the progression and prognosis of GBM. Methods We used univariate Cox proportional hazards regression and stepwise regression algorithm to develop a lymphocyte activation-associated gene signature in the training data set (TCGA, n = 525). Then, the signature was validated in two data sets, including GSE16011 (n = 150) and GSE13041 (n = 191) by the Kaplan Meier method. Univariate and multivariate Cox proportional hazards regression models were used to adjust for clinicopathological factors. Results In the training data set, we identified a lymphocyte activation-associated gene signature (TCF3, IGFBP2, TYRO3 and NOD2), which classified the patients into high-risk and low-risk groups with significant differences in overall survival (median survival 15.33 months vs 12.57 months, HR = 1.55, 95% CI = 1.28-1.87, logrank test P < 0.001). In the other two data sets, this signature showed similar prognostic values. Further, univariate and multivariate Cox proportional hazards regression models analysis indicated that the signature was an independent prognostic factor for GBM patients.Moreover, we found that there were differences in lymphocyte activity between the high- and low-risk groups of GBM patients among all data sets. Furthermore, by longitudinal analysis, the lymphocyte activationassociated gene signature could significantly predict the survival of patients with some features, such as IDH-wildtype patients and patients with radiotherapy. In addition, the signature could improve prognostic power of age. Conclusions In summary, our results suggested that the lymphocyte activation-associated gene signature is a promising factor for the survival of patients, which may be helpful for diagnosis, prognosis, and treatment of GBM patients.
Research Square Platform LLC
Title: Prognostic Impact of a Lymphocyte Activation-Associated Gene Signature in GBM based on Transcriptome Analysis
Description:
Abstract
Background Glioblastoma multiforme (GBM) is the most aggressive primary central nervous system malignant tumor that has poor prognosis.
Lymphocyte activation played important roles in cancer and therapy.
Objective To identify an efficient lymphocyte activation-associated gene signature that could predict the progression and prognosis of GBM.
Methods We used univariate Cox proportional hazards regression and stepwise regression algorithm to develop a lymphocyte activation-associated gene signature in the training data set (TCGA, n = 525).
Then, the signature was validated in two data sets, including GSE16011 (n = 150) and GSE13041 (n = 191) by the Kaplan Meier method.
Univariate and multivariate Cox proportional hazards regression models were used to adjust for clinicopathological factors.
Results In the training data set, we identified a lymphocyte activation-associated gene signature (TCF3, IGFBP2, TYRO3 and NOD2), which classified the patients into high-risk and low-risk groups with significant differences in overall survival (median survival 15.
33 months vs 12.
57 months, HR = 1.
55, 95% CI = 1.
28-1.
87, logrank test P < 0.
001).
In the other two data sets, this signature showed similar prognostic values.
Further, univariate and multivariate Cox proportional hazards regression models analysis indicated that the signature was an independent prognostic factor for GBM patients.
Moreover, we found that there were differences in lymphocyte activity between the high- and low-risk groups of GBM patients among all data sets.
Furthermore, by longitudinal analysis, the lymphocyte activationassociated gene signature could significantly predict the survival of patients with some features, such as IDH-wildtype patients and patients with radiotherapy.
In addition, the signature could improve prognostic power of age.
Conclusions In summary, our results suggested that the lymphocyte activation-associated gene signature is a promising factor for the survival of patients, which may be helpful for diagnosis, prognosis, and treatment of GBM patients.
Related Results
Abstract 4300: Cell cycle pathway gene regulation in glioblastoma multiforme (GBM) and GBM derived stem cells: Implicating Pentraxin 3 upregulation
Abstract 4300: Cell cycle pathway gene regulation in glioblastoma multiforme (GBM) and GBM derived stem cells: Implicating Pentraxin 3 upregulation
Abstract
Introduction: Glioblastoma Multiforme (GBM) is the most aggressive type of brain cancer and progresses at a rapid rate. The major obstacle in the treatment ...
Increased life expectancy of heart failure patients in a rural center by a multidisciplinary program
Increased life expectancy of heart failure patients in a rural center by a multidisciplinary program
Abstract
Funding Acknowledgements
Type of funding sources: None.
INTRODUCTION Patients with heart failure (HF)...
Abstract 1249: SetD2 histone methyltransferase mutation status predicts treatment response in glioblastoma: Strategies to overcome chemoresistance
Abstract 1249: SetD2 histone methyltransferase mutation status predicts treatment response in glioblastoma: Strategies to overcome chemoresistance
Abstract
Purpose: Glioblastoma (GBM) is a highly aggressive primary brain tumor. A major challenge in GBM treatment is tumor resistance to radiation and chemotherapy...
Identification of a Potential Prognostic Signature based on Immune-related Genes in Primary Glioblastoma
Identification of a Potential Prognostic Signature based on Immune-related Genes in Primary Glioblastoma
Abstract
Background: Glioblastoma (GBM) is a common primary brain tumor with a high incidence in adults with malignant and fast-growing biological characteristics. In this ...
Abstract 1260: Tumor hypoxia conditions glioblastoma cells for immunosuppression
Abstract 1260: Tumor hypoxia conditions glioblastoma cells for immunosuppression
Abstract
Glioblastoma (GBM) is the most common and lethal malignant brain tumor that invariably recurs after standard therapy, with a median survival of only ~16 mon...
Molecular and clinicopathological characterization of a prognostic immune gene signature associated with MGMT methylation in glioblastoma
Molecular and clinicopathological characterization of a prognostic immune gene signature associated with MGMT methylation in glioblastoma
AbstractBackgroundO6-methylguanine-DNA methyltransferase (MGMT) methylation status affects tumor chemo-resistance and the prognosis of glioblastoma (GBM) patients. We aimed to inve...
Identification and Validation of Immune-Related Gene Prognostic Signature for breast cancer
Identification and Validation of Immune-Related Gene Prognostic Signature for breast cancer
Abstract
Background
Although the outcome of breast cancer patients has been improved by advances in early detection, diagnosis and treatment. Due to the heterogeneity of t...
BIOM-06. IDENTIFICATION OF AN INFLAMMATORY BIOMARKER SIGNATURE IN PLASMA-DERIVED EXTRACELLULAR VESICLES OF GLIOBLASTOMA PATIENTS
BIOM-06. IDENTIFICATION OF AN INFLAMMATORY BIOMARKER SIGNATURE IN PLASMA-DERIVED EXTRACELLULAR VESICLES OF GLIOBLASTOMA PATIENTS
Abstract
Diagnosis of Glioblastoma (GBM) remains a clinical challenge, currently relying on symptomatic presentation of the tumour, brain imaging and invasive biopsy...

